Mineralys targets December 2026 lorundrostat approval as payer engagement and data drive launch strategy
Source: SeekingAlpha
2026-03-12 19:33:00 ET
More on Mineralys Therapeutics
- Mineralys Therapeutics, Inc. (MLYS) Q4 2025 Earnings Call Transcript
- Mineralys: Pre-NDA Feedback Sets Stage For A Pivotal 2026
- Mineralys spikes as blood pressure drug undergoes FDA review
- Seeking Alpha’s Quant Rating on Mineralys Therapeutics
- Historical earnings data for Mineralys Therapeutics
Read the full article on Seeking Alpha
For further details see:
Mineralys targets December 2026 lorundrostat approval as payer engagement and data drive launch strategy
Mineralys Therapeutics Inc.
NASDAQ: MLYS
MLYS Trading
-2.69% G/L:
$26.40 Last:
398,686 Volume:
$25.81 Open:
MLYS Latest News
March 12, 2026 04:05:00 pm
Mineralys Therapeutics Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update
MLYS Stock Data
$2,458,878,433
58,911,783
0.83%
65
N/A
Biotechnology & Life Sciences
Healthcare
US
Radnor
